Oncternal Therapeutics, Inc. (ONCT)
Market Cap | 20.87M |
Revenue (ttm) | 1.15M |
Net Income (ttm) | -36.38M |
Shares Out | 2.96M |
EPS (ttm) | -12.26 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 15,125 |
Open | 6.84 |
Previous Close | 6.87 |
Day's Range | 6.46 - 7.76 |
52-Week Range | 5.57 - 13.20 |
Beta | 1.38 |
Analysts | Strong Buy |
Price Target | 28.33 (+301.84%) |
Earnings Date | Aug 8, 2024 |
About ONCT
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (C... [Read more]
Financial Performance
In 2023, ONCT's revenue was $785,000, a decrease of -47.32% compared to the previous year's $1.49 million. Losses were -$39.48 million, -10.62% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ONCT stock is "Strong Buy." The 12-month stock price forecast is $28.33, which is an increase of 301.84% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/m/c/press14-2454882.jpg)
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...
![](https://cdn.snapi.dev/images/v1/b/e/press17-2422459.jpg)
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provid...
![](https://cdn.snapi.dev/images/v1/p/b/press20-2407536.jpg)
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...
![](https://cdn.snapi.dev/images/v1/g/i/press3-2402797.jpg)
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...
![](https://cdn.snapi.dev/images/v1/l/p/press11-2378177.jpg)
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno...
![](https://cdn.snapi.dev/images/v1/j/i/press14-2326431.jpg)
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno...
![](https://cdn.snapi.dev/images/v1/n/t/press12-2314134.jpg)
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today prov...
![](https://cdn.snapi.dev/images/v1/q/e/press17-2302259.jpg)
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/w/c/press17-2263210.jpg)
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/k/y/press11-2220307.jpg)
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/p/q/press13-2216452.jpg)
Oncternal Therapeutics Announces Reverse Stock Split
SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/z/s/press8-2208024.jpg)
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updat...
![](https://cdn.snapi.dev/images/v1/c/c/press7-2150868.jpg)
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provi...
![](https://cdn.snapi.dev/images/v1/o/f/press19-2137518.jpg)
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/u/y/press12-2122734.jpg)
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/g/d/press18-2119743.jpg)
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/w/g/press18-2092188.jpg)
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/t/4/press8-2053598.jpg)
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno...
![](https://cdn.snapi.dev/images/v1/2/e/press3-2018279.jpg)
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provi...
![](https://cdn.snapi.dev/images/v1/u/3/press11-2005916.jpg)
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/6/j/press5-2005648.jpg)
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/j/o/press1-1923629.jpg)
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma
SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou...
![](https://cdn.snapi.dev/images/v1/l/v/press15-1915412.jpg)
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...
![](https://cdn.snapi.dev/images/v1/o/s/press10-1872727.jpg)
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provid...
![](https://cdn.snapi.dev/images/v1/p/4/press16-1859529.jpg)
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno...